PaxMedica (NASDAQ: PXMD) recently released an insightful video detailing the outcomes of its Phase 2 study on autism spectrum disorder (“ASD”), initially published in the Annals of General Psychiatry. “This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin intravenous infusions as a breakthrough treatment for ASD… Focused on evaluating the efficacy and safety of suramin intravenous infusions, the study’s 10 mg/kg suramin arm displayed promising results in improving core symptoms of ASD, showcasing statistically significant improvements in the Clinical Global Impressions-Improvement (‘CGI-I’) scale compared to the placebo group,” a recent article explains. “PaxMedica’s unwavering commitment to pioneering research in neurological disorders is highlighted in the video release, demonstrating the company’s dedication to enhancing the quality of life for individuals living with ASD.”
To view the full article, visit https://ibn.fm/KgpMT
About PaxMedica Inc.
PaxMedica is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (“APT”) aimed at addressing a range of challenging neurologic disorders, including autism spectrum disorder (“ASD”) and human African trypanosomiasis (“HAT”). Its portfolio encompasses critical areas within the neurology field, with a focus on pioneering advancements in both ASD and HAT treatments. The company is dedicated to the continuous development and evaluation of its pioneering program, PAX-101-an intravenous suramin formulation that lies at the heart of its efforts, particularly focused on innovative ASD and HAT treatment solutions. PaxMedica’s ongoing research initiatives not only prioritize the needs of ASD and HAT patients but also extend to exploring potential therapeutic applications for related conditions. For more information about the company, visit www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
